Aspirin: what do we know so far? What is new this week? This article discusses the data published this week on the harms of low-dose aspirin, and particularly the harms with increasing age. It also looks at the benefits of aspirin in cardiovascular disease and for cancer, and discusses some of the concerns about PPI use with aspirin. I am well aware that for non-cardiac vascular disease, clopidogrel, or an alternative agent, is now usually first line. But of course the longest and largest data comes from the aspirin trials, and hence the focus on aspirin. Aspirin in CVD: benefits The best data on the benefits of aspirin in CVD comes from the ATTC trials (Lancet 2009:373:1849 & 1821). For secondary prevention of CVD, compared with no treatment: o You need to treat 66 people with aspirin daily for 1 year to prevent 1 CV event (NNT 66/y). o You need to treat 344 people every day for 1 year to prevent 1 CV death (NNT 344/y). These NNTs indicate we should offer aspirin (or an alternative antiplatelet) for secondary prevention of CVD. For primary prevention of CVD, compared with no treatment: o Aspirin is no longer used for the primary prevention of CVD because the benefit is too small. You need to treat 1666 people with aspirin daily for 1 year to prevent 1 CV event (NNT 1666/y). High-risk individuals (hypertensives, diabetics) do not get significantly more benefit than low-risk individuals. There is no reduction in CV mortality with aspirin use in primary prevention. Aspirin in CVD: harms Harms of low-dose aspirin: o For every 3333 people treated with aspirin for 1 year, there would be 1 additional significant bleed (NNH 3333/y) (Lancet 2009:373:1849 & 1821). However, the latest data suggests the risks depend on age. This large UK-based population cohort study of those who had had a CV event (TIA, ischaemic stroke, MI) assessed the harms from antiplatelets (mainly aspirin). The strength of the research is that it looked at risks based on age (Lancet 2017, doi.org/10.1016/s0140-6736(17)30770-5). The study showed: The harms of aspirin increase with age. o The risks were as follows (note the different age ranges in the right-hand column): Annual risk of major bleed <75y 85y Risk of major bleed/year 1% 4% Cumulative risk over 10y <75y 75y Risk of a major GI bleed over 10y 2% 9% Risk of major intracranial bleed over 10y 1% 3% The risk of minor bleeds was similar across all age groups. The outcomes after such events were also worse in older people: bleeds were 10x more likely to be disabling or fatal in those aged 75y or older. This is an important shift in thinking: until now, GI bleeds were considered to rarely be associated with significant long-term harm. Mitigating the risks with PPIs The researchers estimated the benefits of PPIs based on the only published meta-analysis of relevant RCTs, and found that for those taking aspirin for CVD secondary prevention: PPIs offer significant benefits in the older population who are taking aspirin: o For those under 65y: you need to treat 338 people with a PPI daily for 5y to prevent 1 disabling or fatal GI bleed. o For those over 85y: you need to treat 25 people with a PPI and aspirin daily for 5y to prevent 1 disabling or fatal GI bleed. On the basis of this data, the authors suggested that age 75 would be a good time to suggest starting a PPI in those requiring antiplatelets.
Do PPIs inhibit the action of aspirin? Possibly! Some data from cohort studies suggests that PPIs impair aspirin function (remember, cohort studies only show associations, not causation) (BMJ 2011;342:d2690). In those who had had an MI, those on aspirin and a PPI, compared with aspirin alone, were at increased risk of reinfarction. This applied to all the PPIs. The risk increase was small (a 1.5-fold increase in CV events/death as a composite endpoint). H2RA did not increase the risk of re-infarction. The mechanism of action may be through affecting aspirin absorption by changing the acidity of the stomach or interfering with aspirin s ability to interact with platelets. No one is suggesting we stop using PPIs with aspirin, but perhaps we should only use them if there is a good indication (and age may be one of those indications, based on the data above). In addition, there are other concerns about PPIs (these are discussed in more detail in the Gastroenterology chapter on www.gpcpd.com). Aspirin for cancer Aspirin for cancer prevention (Annals Oncol 2015;26:47). Aspirin reduces incidence of, and mortality from, cancer. For every 29 people over the age of 55y who take aspirin for 5y, there will be 1 less cancer death 20y later. Aspirin has the greatest impact on colorectal, oesophageal and gastric cancers. It has a weaker impact on lung, breast and prostate cancer. After the age of 50, the benefits seem to build over time, being greatest after 10y of aspirin use, and continuing even when aspirin is stopped. No benefits are seen before the age of 50. Harms increased with age. Benefits were slightly greater in men than women, and also increased with increasing age. If 1000 people take aspirin daily from age 55y for 10y and then stop, at aged 75y, compared with no aspirin, there will be: Benefits Harms 16 fewer cancer deaths 1 less heart attack Aspirin has also been shown to: 1 fatal stroke 1 fatal GI bleed Reduce distant metastatic spread, but not local or regional spread. The benefit was greatest for GI cancers (Lancet 2012;379:1591, Lancet Oncol 2012;13(5):518). Prevent colon cancer. NNT=57/5y (57 people have to take aspirin for 5y to prevent 1 death from colon cancer) (Lancet 2010;376:1741 (few women in this trial)). The Women s Health Study showed reduced colon cancer incidence, but not mortality, with 100mg aspirin on alternate days (Ann Int Med 2013;159:77). Reduce mortality in those with established colon cancer. NNT=20/10y (20 people diagnosed with colorectal cancer have to take aspirin for 1 extra to survive 10y) (JAMA 2009;302:649). What dose? There have been no head-to-head trials comparing different doses of aspirin in cancer, but doses as low as 75mg have shown benefit. Higher doses have not shown clear additional benefits, but are known to increase the risk of harm (Annals Oncology 2015;26(1):47). For how long? For cancer prevention, incidence starts to fall after 3y, and mortality after 5y. (Annals Oncology 2015;26(1):47). Why might aspirin prevent cancer? Aspirin inhibits COX-2 which is expressed in some tumours. So would you take aspirin for cancer prevention? There is no national guidance suggesting people use aspirin for this indication. However, when we teach this research on our GP Update courses, about 50 70% of our audiences indicate that if they were 55 years old, and had no contraindications, they would be inclined to take low-dose aspirin for cancer prevention. What does all this mean in practice? Aspirin should NOT be used in primary prevention of CVD, even in high-risk populations such as hypertensives and diabetics.
Aspirin (or an alternative antiplatelet) should be used in secondary prevention of CVD, provided there is not a good contraindication. Aspirin reduces the risk of cancers, particularly GI cancers. However, there is no national guidance suggesting people use it for this indication. When aspirin is used, the risks of major bleeds increase with age, and the outcomes are much worse with a 10- fold increased risk of a disabling or fatal outcome after a significant bleed in those over 75y compared with those under 75y. PPI use reduces the risk of significant bleeds in those on aspirin, and the benefits are much greater in older people who are at highest risk. On the basis of this data, the authors suggested that age 75 would be a good time to suggest starting a PPI in those requiring antiplatelets. How about auditing those on aspirin (and perhaps other antiplatelet agents) aged 75 and over to see how many are on PPIs? TH FI Aspirin in CVD prevention and cancer Aspirin is no longer used in primary prevention of CVD as the benefits are too small (NNT 1666/y). This also applies in high-risk primary prevention populations such as those with diabetes and hypertension. Aspirin is beneficial in secondary prevention (NNT 66/y to prevent 1 CV event, NNT 344/y to prevent 1 CV death). The harms from aspirin have been considered to be low, but recent evidence suggests that the risk increases with age, and any adverse events have much greater consequences in older people with a 10-fold risk of disability/fatal outcomes after a significant GI bleed in those aged 75 and over. PPI use reduces the risk of significant bleeds in those on aspirin, and the benefits are much greater in older people who are at highest risk. On the basis of the latest study, the authors suggest that those aged 75 and over on aspirin should be on a PPI. Aspirin reduces the risk of cancer: for every 29 people over 55y treated with low-dose aspirin for 5y, there will be 1 less cancer death at 20y. However, this is not part of any national guidance (yet!). You could audit those on PPIs aged 75 and over who are on aspirin (and perhaps other antiplatelet agents) to see how many are on PPIs. MN My notes leave blank We make every effort to ensure the information in these pages is accurate and correct at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular check drug doses, side effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in these pages. GP Update Limited June 2017
OUR AUTUMN 2017 COURSES Our comprehensive one-day update courses for GPs, GP STs, and General Practice Nurses. We do all the legwork to bring you up to speed on the latest issues and guidance. All our courses are: Relevant Developed and presented by practising GPs and immediately relevant to clinical practice. Challenging Stimulating and thought-provoking. Unbiased Completely free from any pharmaceutical company sponsorship. Fun! Humorous and entertaining without compromising the content! Are they for me? Our courses are designed for: GPs, trainers and appraisers preparing for appraisal and revalidation or wanting to keep up to date across the whole field of general practice. GP ST1, 2 & 3, looking for the perfect launch pad into general practice and help with AKT and CSA revision. GPs who want to be brought up to speed following maternity leave or a career break. General Practice Nurses, especially those seeing patients with chronic diseases. Matt/The Daily Telegraph 2017 Telegraph Media Group Ltd What s included? 6 CPD credits in a lecture-based format, with plenty of time for interaction, humour and video clips, to keep you focussed and awake. A printed copy of the relevant handbook including the results of the most important research in primary care over the last 5 years and covering the subjects more extensively than possible in the course. 12 months subscription to www.gpcpd.com. With three times the content of the handbook, it allows you to capture CPD credits as you read on the site and use it in consultations! It also comes with Focused Learning Activities - online learning activities to provide evidence for your appraisal and earn hundreds of further hours of CPD credits. Buffet lunch and refreshments throughout the day! What s not included? Our courses contain NO theorists, NO gurus, NO sponsors, NO reps on the day! Just real-life GPs who will be back at the coal face as soon as the course has finished. www.gp-update.co.uk
OUR AUTUMN 2017 COURSES The GP Update Course our flagship course! With the amount of evidence and literature inundating us, it can be hard to know which bits should change our practice, and how. The GP Update Course is designed to be very relevant to clinical practice and help you meet the requirements for revalidation. We collate and synthesise the evidence for you so you don t have to! Using a lecture based format, with plenty of time for interaction, the GP presenters discuss the results of the most important evidence and guidance, placing them in the context of what is already known about this topic. The presenters also concentrate on what it means to you and your patients in the consulting room tomorrow. Oxford Fri 29 Sept Fri 13 Oct Southampton Sat 30 Sept Birmingham Sat 14 Oct Cardiff Wed 4 Oct Cambridge Tues 17 Oct Thur 5 Oct Wed 18 Oct Fri 6 Oct Nottingham Thur 19 Oct Sat 7 Oct Inverness Wed 1 Nov Leeds Wed 11 Oct Edinburgh Thur 2 Nov Liverpool Thur 12 Oct Glasgow Fri 3 Nov The MSK and Chronic Pain Update Course - New MSK problems are the most common reason for seeing a GP and represent 30% of repeat GP visits. We want to help build your confidence. On the course we will tackle: The evidence-base for common MSK conditions including osteoarthritis, spondyloarthritis, polymyalgia, fibromyalgia and much more. Diagnosis: why waddling like a duck might help; and what to do when there is no diagnosis! Why chronic pain is in the brain and more importantly, what we and our patients can do about it. We will provide you with a new narrative and a tool box of strategies you can take back to the surgery and start using the next day. Thur 30 Nov Fri 1 Dec Lead. Manage. Thrive! The management skills course for GPs Many of us have chosen to be salaried or portfolio GPs yet feel impotent or looked over when it comes to contributing to the effective running of our practices. We become frustrated and feel that we have little or no influence over what happens. It s not your fault, most GPs (experienced and new) have had very little training in management and leadership skills for clinical practice. Here s the good news, all of us lead whether in an official or unofficial role. Who is this course for? GPs at every stage in their career who aren t quite sure how to get unstuck! Also highly relevant to anyone who recognises the need to build their personal resilience and leadership skills to meet the demands of modern primary care, i.e. practice managers, nurses, and administrative and support teams. As usual Red Whale has done all the legwork to bring you a concise, practical and actionable one-day course and handbook. Not only have we trawled through lots of relevant management, leadership and development literature, but we have also distilled its content through the lens of real GPs, enabling you to apply it to the reality of your practice. Southampton Thur 16 Nov Oxford Thur 23 Nov Fri 17 Nov Fri 24 Nov
OUR AUTUMN 2017 COURSES The Cancer Update Course Within the next 15 years the need for cancer care will double and you will look after as many cancer survivors as diabetics. Shared care follow up will become the norm, and secondary care will pass responsibility to us. A key 2015 Lancet Oncology commission paper warned that: GPs are inadequately trained and resourced to manage the growing demand for cancer care in high income countries. Education for GPs was one of their five key recommendations we can help you get ahead of the curve! Established GPs and GP STs can use this course to bridge the gap in traditional GP cancer education which has focussed heavily on referral and end of life care missing out the whole journey in between. This course is able to look in much more detail at the big picture behind the disease perhaps most feared by our patients and, let s face it, that 1 in 2 of us will be diagnosed with over our lifetime. Nottingham Norwich Thur 9 Nov Fri 10 Nov Wed 15 Nov Thur 16 Nov Fri 17 Nov The Women s Health Update Course From the pill to pelvic pain, periods and prolapses, the one day Women s Health Update course is a comprehensive guide to understanding and managing common gynaecological problems in general practice. Using a case-based approach will give you the skills to manage your female patients in a real surgery. We aim to make the day fun, interactive as well as educational. You will leave the course feeling more confident, knowledgeable and with a much stronger pelvic floor!!! The day is designed for all GPs and GP STs not just those with a special interest! Leeds Nottingham Thur 2 Nov Fri 3 Nov Thur 9 Nov Fri 10 Nov Fri 17 Nov Our Consultation Skills Courses One day small group courses designed for GPs, GP STs and General Practice Nurses. The courses have a practical focus and lots of engaging exercises allowing delegates to rehearse the most effective consultation behaviours. But don t worry, there won t be any role playing in front of everybody! For more information on each course, please visit www.gp-update.co.uk/courses The Telephone Consultation Course Fri 6 Oct Fri 13 Oct Glasgow Sat 4 Nov The Effective Consultation Course Leeds Wed 4 Oct Fri 24 Nov Prices GP Update Course: GP 195 GP Registrar 150 Nurse 150 All other courses: 225 or 210 for members of www.gpcpd.com (GPCPD members, please log in and then click on the relevant button within the Member information box on the right of the home screen to get your discount code) Join the Red Whale pod Plan ahead! Save 60 when you book three courses in 2017. Use discount code 3BUNDLE2017 when booking via www.gp-update.co.uk or by phone 0118 960 7077.* *Not to be used in conjunction with any other promotional codes.
GPCPD.com - your appraisal and revalidation all under one roof! Red Whale has joined forces with FourteenFish to bring you a seamless approach to the appraisal and revalidation process. Subscribe to GPCPD to improve your learning journey and take advantage of these partnership benefits: 12 months access to the course online handbook and focussed learning activities to gain additional credits. Seamless appraisal integration just link your GPCPD account to FourteenFish and any learning you record in GPCPD will be automatically added to your appraisal. Exclusive 15% off FourteenFish Appraisal Toolkit switch to this nimble and userfriendly toolkit for only 35.70 a year, and All of the above is included with your GPCPD subscription, FREE for 12 months when you attend a Red Whale course. Not able to attend a course, but would still like access to the benefits? Subscribe to GPCPD for just 85 for 12 months. Sign up now - www.gp-update.co.uk/gpcpd with a free switching service from your existing appraisal system, it s a real catch! Effortless CPD recording access to the FourteenFish Learning Diary app, to track your CPD from your smartphone and on the move. Access to surveys and tools for your revalidation FourteenFish offers quick and simple to set up peer review and patient surveys to help you with revalidation. To book: online at www.gp-update.co.uk or call us on 0118 960 7077 or use the form below. I would like to come on the following course(s) (please write legibly!): The GP Update Course The MSK and Chronic Pain Update Course Lead. Manage. Thrive! Course The Cancer Update Course The Women s Health Update Course The Telephone Consultation Course The Effective Consultation Course I can t attend a course, but would like to order your Handbook or DVD: GP Update Handbook and 12 months access to GPCPD 150 GP Update Handbook, DVD and 12 months access to GPCPD 225 (pre-order for delivery late May 2017.) Lead. Manage. Thrive! Handbook 70 Women s Health Update Handbook 70 Cancer Update Handbook 70 Name... Address...... Email... (Please write your email address clearly as we ll use it to send your confirmation letter and receipt.) Price as stated in the flyer for each course. If applicable, please provide your discount code here... Please send this form with your cheque payable to GP Update Limited to: Red Whale, University of Reading, Reading Enterprise Centre, Earley Gate Entrance, Whiteknights Road, Reading, Berkshire RG6 6BU GP Update Limited, registered in England and Wales No. 7135974. Registered Office: Prospect House, 58 Queens Road, Reading RG1 4RP Full terms and conditions are available at www.gp-update.co.uk Relevant challenging BMJ/240617 and fun!